Cardiovascular
ICON's cardiovascular trial experience, supported by a global team of experts
A multifaceted risk factor: Addressing obesity's impact across the disease spectrum
With obesity as a risk factor across the disease spectrum, there are several unique considerations and strategies for sponsors and researchers to account for in their approach to development and clinical trials for obesity treatment.
From genomics to the coming of age glycomics
Discover how glycan biomarkers are quickly becoming key elements of cancer, cardiovascular, and gastrointestinal research, setting the stage for a new golden age of epigenetic research and personalised therapeutics.
Mitigating the impact of COVID-19 on cardiovascular trials
COVID-19 has had a significant impact on the conduct of clinical trials and participants. Participants in cardiovascular (CV) trials typically are older, with underlying CV disease or risk factors such as hypertension and diabetes – a population at higher risk of death from COVID-19 if they contract the virus. As a result, these individuals may have heightened concerns about participating in a clinical trial due to the potential for exposure to COVID-19. Discover measures that can be implemented in ongoing trials to ensure the safety of participants, maximise retention and maintain trial integrity
Thriving in Value-Based Healthcare: A guide for cardiovascular medical device manufacturers
In December 2016, the Centers for Medicare & Medicaid Services (CMS) expanded the Bundled Payments for Care Improvement (BPCI) Initiative to include cardiovascular and hip fracture services, taking a major step in the march towards value-based care in the US. Read how can medical device manufacturers sustain growth and successfully navigate this new model?
Reimagining patient-centric clinical trials with the IoMT
Follow a theoretical patient through the entire clinical trial journey – from initial contact for an early study through transition to treatment with an approved product. At each stage, we explore how IoMT can increase clinical development programme efficiency by reducing the burden on patients, caregivers, pharma companies and medical device and diagnostic manufacturers.
Cardiovascular event adjudication during COVID-19 and beyond
In this webinar you will learn more about best practices for cardiovascular event adjudication across drug and device trials, including recent advances in the selection and application of connected devices.
Latest on Cardiovascular, Metabolic, and Circulation
If you would like to receive our Cardiovascular email updates, including the latest on cardiovascular clinical trials, click here to go to our preference centre.
Blogs and media articles relating to cardiovascular and metabolic clinical trials
-
Blog: Diabesity: Overlapping pathophysiology informs multi-indication treatment
As recognition of the overlap between obesity and diabetes has grown, so have efforts to develop treatments that can treat the two conditions in tandem.
-
Media article: Overcoming challenges in obesity-related clinical trials
Recent advancements in obesity treatments have spotlighted the field for healthcare providers and developers. In this article from Drug Discovery World, ICON experts share insights on the clinical trials landscape for obesity and why patient centricity is key to overcoming common challenges in the sector.
-
Media article: Insight into obesity-related clinical research
In an interview with Contract Pharma, ICON’s Adrienne Stoudenmire and Alan Baldridge discuss current obesity R&D trends, challenges associated with obesity-related clinical research, and opportunities in this sector.
-
Media article: ICON Survey Stresses Combo Therapies in Obesity Care
This news piece from The Clinical Trial Vanguard provides an overview of the findings from ICON’s recent survey of professionals engaged in obesity-related clinical research. It outlines that most respondents believe that obesity therapy trials should measure multiple outcomes due to the overlap between obesity and related comorbidities.
-
Media article: ICON Announces Results from Survey on Obesity-related Clinical Research
This news article, from Applied Clinical Trials, outlines findings from ICON’s recent survey of over 100 industry professionals on their opinions on future research within the therapeutic area of obesity treatment.
-
Media article: Diabesity: Implications for treatment and drug development
In this Journal for Clinical Studies’ article, Simon Bruce and Jack Martin discuss the overlap in pathophysiology and treatment of diabetes and obesity along with considerations for streamlining the clinical development of treatments that have therapeutic promise for both conditions.
-
Blog: Realising the benefits of bringing decentralised cardiovascular trials to patients
This blog reflects on the success of the first fully decentralised cardiovascular trial during the COVID-19 pandemic and highlights key elements for future trials.
-
Media article: Glycomics applications reinforce precision medicine
Nicole A. Cowan explores how glycomics is joining genomics and proteomics in the study of disease mechanisms and the development of novel therapeutics.
-
Blog: Data disruption: Navigating cardiovascular clinical trial adjudication during a respiratory pandemic
The COVID-19 pandemic disrupted clinical trials across all indications. For trials that persevered, COVID-19 impacted patient enrollment, participation, and data collection.
-
Media article: Ensuring Patient Safety and Cardiovascular Clinical Trial Integrity during a Global Pandemic
ICON experts share insights on ensuring patient safety and cardiovascular clinical trial integrity during the COVID-19 pandemic.
-
Blog: Managing trial participants with cardiovascular and metabolic disease during COVID-19
ICON recognises that the COVID-19 pandemic will have an impact on the conduct of ongoing and newly initiating clinical trials.
-
Media article: Mitigating the impact of COVID-19 on CV trials and participants
A thought leadership article authored by Jack Martin, Mary Jane Geiger and Deirdre Albertson which focuses on navigating cardiovascular clinical trials during COVID-19.
-
Blog: Digital health technologies - Implementing innovation in cardiovascular studies during COVID-19
ICON experts discuss how the COVID-19 pandemic has led to the implementation of more efficient cardiovascular (CV) trial designs and operational execution.
-
Media article: Adopting mHealth technologies in CV trials
The article discusses how, with the right approach and expert guidance, mHealth can help to collect new types of data and make trials more patient centric.
-
Blog: Reducing disruptions of cardiovascular trials and ensuring trial integrity during a global pandemic
Lessons learnt from Alzheimer’s trials could help in Parkinson’s drug development.
-
Blog: COVID-19, influenza and cardiovascular disease
Patients with cardiovascular disease are particularly susceptible to respiratory infections.
Cardiovascular clinical trials services at ICON
ICON has over 25 years' experience conducting cardiovascular trials, with particular emphasis on key cardiovascular/metabolic indications: heart failure, lipid disorders, diabetes, renal insufficiency and renal transplant, arrhythmia, and rare diseases.